Available online on 15.07.2024 at ijmspr.com

International Journal of Medical Sciences and Pharma Research

Open Access to Medical Science and Pharma Research

Copyright  © 2024 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Iron Overload in HIV: Clinical Challenges and Management Approaches

Emmanuel Ifeanyi Obeagu *

Department of Medical Laboratory Science, Kampala International University, Uganda. 

 

 

Introduction

Iron is a critical element required for various physiological functions, including oxygen transport, DNA synthesis, and cellular energy production. The body tightly regulates iron homeostasis through mechanisms involving absorption, transport, and storage to prevent both deficiency and toxicity. Disruptions in this delicate balance can lead to either iron deficiency or overload, each of which can significantly impact overall health. In HIV-infected individuals, iron metabolism is particularly affected due to the chronic inflammatory state induced by the virus, leading to complex interactions between iron homeostasis and disease progression.^1-2 Human Immunodeficiency Virus (HIV) primarily targets CD4+ T cells, leading to progressive immunodeficiency and increased susceptibility to opportunistic infections. The chronic inflammation associated with HIV infection alters iron metabolism in several ways. Increased levels of inflammatory cytokines, such as interleukin-6 (IL-6), stimulate the production of hepcidin, a key regulator of iron homeostasis. Elevated hepcidin levels lead to reduced iron absorption and sequestration of iron within macrophages and hepatocytes, contributing to iron overload despite low systemic iron availability.^3-4 Iron overload in HIV-infected patients can result in a range of adverse outcomes. Excess iron provides cofactors necessary for viral replication, potentially enhancing HIV replication rates and accelerating disease progression. Additionally, iron-induced oxidative stress exacerbates cellular damage and inflammation, further compromising immune function. The presence of excess iron can also lead to liver damage, particularly in individuals with co-infections such as hepatitis B or C, complicating the management of both HIV and liver disease.^5-6 The clinical management of iron overload in HIV-infected individuals involves several challenges. Accurate diagnosis of iron overload can be difficult due to overlapping symptoms with other forms of anemia, such as anemia of chronic disease. Distinguishing between iron deficiency anemia and anemia associated with chronic inflammation requires careful assessment of iron parameters and inflammatory markers. Moreover, treatment strategies must balance the need to reduce excess iron while managing anemia and optimizing antiretroviral therapy (ART).^7-8

Phlebotomy and iron chelation therapy are commonly used to manage iron overload. Phlebotomy, the removal of blood to decrease iron levels, is effective but may not be suitable for all patients, particularly those with anemia or contraindications. Iron chelation therapy, using agents such as deferoxamine or deferasirox, can help remove excess iron but requires careful monitoring to avoid side effects. The choice of treatment should be tailored to the individual’s specific needs and overall health status.^9-10 ART regimens can also influence iron metabolism, necessitating careful selection of medications to minimize their impact on iron levels. Some ART drugs can affect iron absorption and utilization, potentially exacerbating iron overload or contributing to anemia. Regular monitoring of blood counts and iron parameters is essential to guide therapy and adjust treatment as needed. Optimizing ART while managing iron dysregulation presents a unique challenge in the comprehensive care of HIV-infected patients.^11-12 Dietary and lifestyle modifications play a crucial role in managing iron levels. Patients are often advised to limit dietary sources of iron, particularly heme iron from animal products, and avoid iron supplements unless specifically prescribed. Additionally, avoiding excessive vitamin C intake is recommended, as it enhances iron absorption. Educating patients on dietary changes and the importance of adherence to treatment plans can significantly impact the management of iron overload. The presence of co-infections, such as hepatitis B or C, further complicates the management of iron overload in HIV-infected individuals. Iron overload can accelerate liver fibrosis and increase the risk of hepatocellular carcinoma, adding to the challenges of managing HIV-associated liver disease. Comprehensive care must include regular monitoring of liver function, appropriate antiviral therapies, and strategies to address both iron overload and liver damage.^13-16

Iron Metabolism and HIV

Iron is an essential mineral that plays a crucial role in various physiological processes, including oxygen transport, DNA synthesis, and energy production. The body maintains iron homeostasis through a tightly regulated system involving absorption, transport, and storage. This balance is critical, as both iron deficiency and excess can have significant health consequences. In the context of HIV infection, iron metabolism becomes particularly complex due to the interplay between the virus-induced inflammatory state and the body's iron regulation mechanisms.^17-18 Iron metabolism is regulated by a network of proteins and hormones that ensure iron is adequately absorbed, transported, and stored. Hepcidin, produced by the liver, is the principal regulator of iron homeostasis. It functions by binding to ferroportin, the only known iron export protein, and inducing its internalization and degradation. This process reduces the release of iron from cells into the bloodstream, thereby limiting iron availability. Hepcidin levels are influenced by various factors, including systemic iron levels, inflammation, and infection.^19-20 In a healthy individual, iron absorption occurs primarily in the duodenum, where dietary iron is absorbed into enterocytes and then transported to the bloodstream. Once in the bloodstream, iron is bound to transferrin, a transport protein that delivers it to various tissues, including the bone marrow for erythropoiesis and the liver for storage as ferritin. This intricate regulation ensures that iron is available for critical processes while minimizing potential toxicity from free iron. HIV infection induces a chronic inflammatory response that significantly disrupts iron homeostasis. The virus's presence triggers the release of inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), which stimulate the production of hepcidin. Elevated hepcidin levels lead to decreased intestinal absorption of iron and sequestration of iron in macrophages and hepatocytes. This results in lower circulating iron levels and contributes to anemia, a common complication in HIV-infected individuals.^21-24

Iron sequestration in macrophages and other immune cells is a defense mechanism to limit the availability of iron to pathogens, including viruses like HIV. However, this response can inadvertently lead to iron overload in the body, particularly when iron stores are not adequately regulated. This paradoxical situation can result in a form of iron dysregulation known as anemia of chronic disease (ACD), where iron is present in the body but not readily available for erythropoiesis.^25-26 The disruption of iron metabolism in HIV-infected individuals can lead to several adverse outcomes. Anemia is a prevalent issue, often exacerbated by the combined effects of chronic inflammation and impaired iron utilization. Anemia can reduce the oxygen-carrying capacity of the blood, leading to fatigue, weakness, and decreased overall health, which can impact a patient’s ability to adhere to HIV treatment and manage other health issues.^27-28 Iron overload, although less common than deficiency, can also pose significant problems. Excess iron can act as a cofactor for viral replication, potentially increasing HIV replication rates and accelerating disease progression. Furthermore, the presence of excess iron can exacerbate oxidative stress, leading to cellular damage and inflammation. This oxidative damage can further compromise immune function and contribute to the progression of HIV-related complications, including liver disease.^29-30 Effective management of iron dysregulation in HIV-infected individuals involves a comprehensive approach. Regular monitoring of iron levels, including serum ferritin and transferrin saturation, is essential for detecting abnormalities early. For patients with iron deficiency, supplementation and treatment for underlying causes are necessary. In cases of iron overload, therapeutic strategies such as phlebotomy or iron chelation therapy may be required to reduce excess iron and mitigate associated complications.^31-32 Optimizing antiretroviral therapy (ART) is also critical, as some ART drugs can influence iron metabolism. Careful selection of ART regimens can help minimize their impact on iron levels while ensuring effective viral suppression. Additionally, managing anemia and iron overload often requires a multidisciplinary approach, involving primary care physicians, infectious disease specialists, and hematologists.^33-34

Impact of Iron Overload on HIV Progression

Iron overload in HIV-infected individuals has significant implications for disease progression, influencing viral replication, immune function, and overall health. The accumulation of excess iron can exacerbate the already complex clinical picture of HIV infection, leading to accelerated disease progression and increased risk of complications.³⁵ Iron plays a crucial role in various biological processes, including the replication of viruses. HIV, like many other viruses, relies on iron-dependent enzymes for its replication. Excess iron provides additional cofactors necessary for these enzymatic processes, potentially enhancing the efficiency of viral replication. Studies have shown that increased iron availability can lead to higher levels of HIV RNA in plasma, suggesting that iron overload may contribute to increased viral load. This heightened replication can accelerate disease progression, leading to more rapid immune system deterioration and increased risk of opportunistic infections.^36-37 The immune system of HIV-infected individuals is already compromised due to the direct effects of the virus on CD4+ T cells. Iron overload can further impair immune function by affecting various immune cells, including macrophages, dendritic cells, and lymphocytes. Excess iron can disrupt the normal functioning of these cells, impairing their ability to present antigens and produce reactive oxygen species (ROS) necessary for pathogen clearance. For instance, iron-loaded macrophages have reduced capacity to kill pathogens and may contribute to persistent inflammation. This impaired immune response can lead to a higher susceptibility to opportunistic infections and a reduced ability to control HIV replication.^38-39 Iron overload is associated with increased oxidative stress, a condition characterized by excessive production of ROS and subsequent cellular damage. Excess iron catalyzes the formation of ROS through Fenton and Haber-Weiss reactions, leading to oxidative damage to cellular components such as lipids, proteins, and DNA. In HIV-infected individuals, oxidative stress is already elevated due to chronic inflammation and the direct effects of the virus. Iron-induced oxidative stress exacerbates this damage, contributing to the progression of HIV-related complications. Additionally, oxidative stress can activate transcription factors such as nuclear factor-kappa B (NF-κB), which enhances the transcription of the HIV genome, further promoting viral replication.^41-42

Iron overload can exacerbate liver damage in HIV-infected individuals, particularly those with co-infections such as hepatitis B or C viruses. These co-infections also utilize iron for replication and can lead to increased iron accumulation in the liver. Excess iron accelerates liver fibrosis and increases the risk of hepatocellular carcinoma, complicating the management of HIV and co-infections. The presence of iron overload can worsen liver function and contribute to the progression of liver disease, further impacting overall health and treatment outcomes.^43-44 Iron overload may influence the efficacy and tolerability of ART in HIV-infected individuals. Some ART drugs can affect iron metabolism and exacerbate iron-related issues. For example, certain medications can influence iron absorption or utilization, potentially contributing to either iron overload or deficiency. Managing iron overload while optimizing ART requires careful selection of medications and regular monitoring of iron levels to avoid adverse interactions and ensure effective viral suppression.^45-46 Iron overload is also linked to cardiovascular complications, which can be of particular concern for HIV-infected individuals. Excess iron can contribute to the development of atherosclerosis and cardiovascular disease through mechanisms involving oxidative stress and inflammation. The presence of cardiovascular disease can further complicate the management of HIV and increase the risk of adverse outcomes. Monitoring cardiovascular health and managing iron levels are essential components of comprehensive care for HIV-infected patients.^47-48 Iron overload can complicate the management of anemia, a common issue in HIV-infected individuals. While iron supplementation is typically used to treat iron deficiency anemia, excess iron can exacerbate iron overload and potentially worsen anemia. Balancing the treatment of anemia with the management of iron overload requires a nuanced approach, including the use of erythropoiesis-stimulating agents and careful monitoring of iron levels.^49-50

Clinical Challenges

The management of iron overload in HIV-infected individuals presents several clinical challenges that complicate both the treatment of HIV and the overall health of patients. These challenges stem from the complex interactions between iron metabolism and HIV, as well as the need to balance various therapeutic strategies. Addressing these challenges effectively requires a comprehensive approach that considers the multifaceted nature of iron dysregulation in the context of HIV infection. Accurately diagnosing iron overload in HIV-infected patients can be challenging due to overlapping symptoms with other conditions. Anemia is common in HIV-infected individuals and can be caused by various factors, including chronic inflammation, nutrient deficiencies, and bone marrow suppression. Differentiating between iron deficiency anemia, anemia of chronic disease, and iron overload requires careful assessment of iron parameters such as serum ferritin, transferrin saturation, and total iron-binding capacity. Additionally, inflammatory markers must be considered to understand the impact of chronic inflammation on iron metabolism. The use of imaging techniques, such as liver MRI, can assist in assessing iron stores and detecting iron accumulation in tissues. However, access to these diagnostic tools and their interpretation can vary, adding to the complexity of diagnosis and management. Regular monitoring and a multidisciplinary approach involving hematologists, infectious disease specialists, and primary care physicians are essential to ensure accurate diagnosis and effective management.⁵¹

Managing iron overload while addressing anemia and optimizing antiretroviral therapy (ART) presents a significant therapeutic challenge. For patients with iron overload, treatments such as phlebotomy or iron chelation therapy are required to reduce excess iron levels. However, these interventions must be carefully balanced with the need to manage anemia, which may also require iron supplementation or erythropoiesis-stimulating agents (ESAs). The risk of exacerbating iron overload while treating anemia requires a nuanced approach and close monitoring of iron parameters. In addition, some ART drugs can affect iron metabolism, potentially exacerbating iron dysregulation. For example, certain medications may influence iron absorption or utilization, complicating the management of iron overload. Careful selection of ART regimens and regular monitoring of blood counts and iron levels are necessary to minimize interactions and optimize treatment outcomes. HIV-infected individuals often have co-infections, such as hepatitis B or C, which can further complicate the management of iron overload. These co-infections also influence iron metabolism and can lead to increased iron accumulation in the liver. Iron overload exacerbates liver damage, accelerating fibrosis and increasing the risk of hepatocellular carcinoma. Managing co-infections requires a comprehensive approach that addresses both the viral infections and associated iron-related complications. Coordination between specialists in infectious diseases, hepatology, and hematology is crucial for effective care. Dietary and lifestyle modifications are important components of managing iron overload, but implementing these changes can be challenging. Patients must be educated about limiting dietary sources of iron and avoiding iron supplements unless prescribed. Additionally, patients need to be informed about the impact of vitamin C on iron absorption and its role in exacerbating iron overload. Ensuring patient adherence to dietary recommendations and lifestyle changes requires ongoing education and support. Iron overload and its management can have psychological and social impacts on patients. The need for regular monitoring, therapeutic interventions, and adherence to dietary restrictions can affect a patient’s quality of life and mental well-being. The stress of managing a chronic illness like HIV, along with the additional burden of iron dysregulation, can lead to feelings of anxiety or depression. Providing psychological support and resources to help patients cope with these challenges is an essential aspect of comprehensive care. Regular monitoring of iron levels and overall health is crucial for managing iron overload and its complications. However, maintaining consistent follow-up can be challenging due to factors such as patient non-adherence, logistical issues, and healthcare access disparities. Implementing effective follow-up strategies and ensuring patients have access to necessary diagnostic and therapeutic resources are key to managing iron overload successfully.⁵²

Management Approaches

Effectively managing iron overload in HIV-infected individuals requires a multifaceted approach that addresses both the iron dysregulation and its interactions with HIV treatment. This involves accurate diagnosis, tailored therapeutic interventions, careful management of antiretroviral therapy (ART), and lifestyle modifications. The following sections outline key strategies for managing iron overload in the context of HIV infection. Measuring serum ferritin, transferrin saturation, and total iron-binding capacity provides insights into iron stores and utilization. Elevated serum ferritin levels combined with normal or high transferrin saturation may indicate iron overload. Non-invasive imaging, such as liver MRI with T2* relaxation or magnetic resonance imaging (MRI) to assess liver iron concentration, can help evaluate iron accumulation in tissues. These methods are useful for diagnosing iron overload and assessing the extent of tissue damage. In some cases, a liver biopsy may be necessary to directly measure iron content and assess liver damage. This is typically considered when non-invasive methods are inconclusive or when there is significant liver involvement. Regular monitoring of iron levels, particularly in patients with chronic HIV infection or those receiving treatments known to affect iron metabolism, is essential for timely intervention and management. For patients with significant iron overload, therapeutic phlebotomy (removal of blood) can be an effective method to reduce iron levels. This approach is suitable for patients who do not have anemia or other contraindications. Phlebotomy should be performed regularly, with the frequency adjusted based on iron levels and overall health. For patients who cannot undergo phlebotomy or have contraindications, iron chelation therapy is an alternative. Agents such as deferoxamine, deferasirox, or deferiprone bind to excess iron and facilitate its excretion. Monitoring for side effects and regular assessment of iron levels are important to ensure efficacy and safety. In cases where iron overload coexists with anemia, balancing treatment is critical. Erythropoiesis-stimulating agents (ESAs) may be used to stimulate red blood cell production, while iron supplementation should be carefully managed to avoid exacerbating iron overload. Some ART medications may influence iron metabolism or interact with iron-chelating agents. Choosing ART regimens that minimize adverse effects on iron metabolism is important for maintaining effective viral suppression while managing iron levels. Regular monitoring of blood counts and iron parameters during ART is essential to detect and address any emerging issues related to iron dysregulation. Adjustments to ART regimens may be necessary based on these findings. Combining ART with therapies specifically targeting iron overload can help manage both HIV and iron-related issues more effectively. Coordination between specialists in infectious diseases and hematology ensures comprehensive care. Patients should be advised to limit dietary sources of heme iron (found in animal products) and avoid excessive vitamin C intake, which enhances iron absorption. A dietitian can provide personalized dietary recommendations based on individual iron levels and overall health. Patients should avoid iron supplements unless specifically prescribed. Supplementation should be monitored closely to prevent exacerbation of iron overload. Regular physical activity and maintaining a healthy lifestyle can help improve overall health and support the management of iron levels. Addressing co-infections with appropriate antiviral therapies can help reduce liver damage and iron accumulation. Coordinating care between infectious disease specialists and hepatologists ensures comprehensive management. Regular liver function tests and imaging are important for monitoring liver health and assessing the impact of iron overload and co-infections on liver function. Providing access to mental health services can help patients cope with the stress and anxiety associated with chronic illness and complex treatment regimens. Educating patients about the importance of adherence to treatment, dietary restrictions, and lifestyle changes can improve outcomes and quality of life.^48-52

Conclusion

Iron overload presents a significant challenge in the management of HIV-infected individuals, impacting disease progression, immune function, and overall health. The complex interplay between HIV infection and iron metabolism underscores the need for a multifaceted approach to diagnosis and treatment. Addressing iron dysregulation effectively requires a careful balance between managing excess iron and optimizing antiretroviral therapy (ART), alongside considerations for co-infections and patient-specific factors. Accurate diagnosis of iron overload involves a combination of iron studies, imaging techniques, and, in some cases, liver biopsy. Regular monitoring is essential to guide treatment decisions and ensure timely intervention. Therapeutic strategies, including phlebotomy and iron chelation therapy, must be tailored to the severity of iron overload and the presence of anemia or other complications. Balancing these treatments with the need to manage HIV effectively adds an additional layer of complexity to patient care.

ART optimization is crucial in managing iron dysregulation, as some medications can influence iron metabolism. Selecting appropriate ART regimens and monitoring their effects on iron levels are integral to achieving effective viral suppression while mitigating iron-related issues. Additionally, managing co-infections such as hepatitis requires a coordinated approach to address both viral infections and iron overload, emphasizing the importance of integrated care. Dietary and lifestyle modifications play a significant role in managing iron overload. Patient education on dietary adjustments, avoidance of iron supplements, and lifestyle changes is vital for supporting treatment efforts and improving patient outcomes. Addressing the psychosocial aspects of living with HIV and iron overload is also important for enhancing quality of life and adherence to treatment.

References

1. Halliday JW, Powell LW. Hemochromatosis and other diseases associated with iron overload. InIron and human disease 2018: 131-160. CRC press. https://doi.org/10.1201/9781351073899-5

2. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).

3. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41

4. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

5. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64

6. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16

7. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32

8. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36

9. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.

10. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26

11. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

12. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35

13. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59

14. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57

15. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15

16. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72

17. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

18. Obeagu EI. Iron Overload in HIV: Impact on Hepatic Function. Elite Journal of Nursing and Health Science. 2023;1(1):24-38. https://doi.org/10.22270/ajdhs.v4i1.63

19. Fuqua BK, Vulpe CD, Anderson GJ. Intestinal iron absorption. Journal of Trace Elements in Medicine and Biology. 2012;26(2-3):115-119. https://doi.org/10.1016/j.jtemb.2012.03.015 PMid:22575541

20. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012;1823(9):1434-1443. https://doi.org/10.1016/j.bbamcr.2012.01.014 PMid:22306005 PMCid:PMC4048856

21. Sundic T, Hervig T, Hannisdal S, Assmus J, Ulvik RJ, Olaussen RW, Berentsen S. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis. Blood Transfusion. 2014;12(Suppl 1):s84.

22. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63

23. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17

24. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35

25. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24

26. Ellis RJ, Marquine MJ, Kaul M, Fields JA, Schlachetzki JC. Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nature Reviews Neurology. 2023;19(11):668-687. https://doi.org/10.1038/s41582-023-00879-y PMid:37816937 PMCid:PMC11052664

27. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937. https://doi.org/10.1097/MD.0000000000036937 PMid:38215133 PMCid:PMC10783375

28. Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine. 2024;2(5):36-52.

29. Obeagu EI. Current Insights into Erythropoietin Levels and Anemia in HIV Patients. Elite Journal of Haematology, 2024; 2 (6).:35-45.

30. Obeagu EI, Obeagu GU. Erythropoietin Signaling and its Implications in HIV-Related Anemia: A Comprehensive Review. Elite Journal of HIV. 2024;2(4):54-71.

31. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.

32. Obeagu EI. Iron Overload in HIV: Impact on Hepatic Function. Elite Journal of Nursing and Health Science. 2023;1(1):24-38. https://doi.org/10.22270/ajdhs.v4i1.63

33. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nature Reviews Microbiology. 2008;6(7):541-552. https://doi.org/10.1038/nrmicro1930 PMid:18552864

34. Liu W, Zhang S, Nekhai S, Liu S. Depriving iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Current clinical microbiology reports. 2020; 7:13-19. https://doi.org/10.1007/s40588-020-00140-w PMid:32318324 PMCid:PMC7169647

35. Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Journal of Immunology Research. 2012;2012(1):784740. https://doi.org/10.1155/2012/784740 PMid:22242039 PMCid:PMC3254022

36. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

37. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.

38. Obeagu EI. Iron Overload in HIV: Implications for Antiretroviral Therapy. Elite Journal of Health Science. 2023;1(1):25-37.

39. Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV. 2024;2(6):1-2.

40. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.

41. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.

42. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.

43. Obeagu EI, Nwosu DC. Hemochromatosis and HIV: Unraveling Genetic Susceptibility. Elite Journal of Medicine. 2024;2(5):36-52.

44. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.

45. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.

46. Obeagu EI. Current Insights into Erythropoietin Levels and Anemia in HIV Patients. Elite Journal of Haematology, 2024; 2 (6).:35-45.

47. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. Elite Journal of Haematology, 2024; 2 (4). 2024:51-67.

48. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.

49. da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World journal of virology. 2015;4(2):56. https://doi.org/10.5501/wjv.v4.i2.56 PMid:25964872 PMCid:PMC4419122

50. Bain BJ. Pathogenesis and pathophysiology of anemia in HIV infection. Current opinion in hematology. 1999;6(2):89. https://doi.org/10.1097/00062752-199903000-00006 PMid:10088638

51. Shahriar S, Araf Y, Ahmad R, Kattel P, Sah GS, Rahaman TI, Sadiea RZ, Sultana S, Islam MS, Zheng C, Hossain MG. Insights into the coinfections of human immunodeficiency virus-hepatitis B virus, human immunodeficiency virus-hepatitis C virus, and hepatitis B virus-hepatitis C virus: Prevalence, risk factors, pathogenesis, diagnosis, and treatment. Frontiers in microbiology. 2022; 12:780887. https://doi.org/10.3389/fmicb.2021.780887 PMid:35222296 PMCid:PMC8865087